BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease

• BioVie highlighted bezisterim, an oral small molecule designed to modulate TNFα-driven inflammation across Parkinson’s disease, Long COVID, and Alzheimer’s disease.
• Topline data expected in 3Q 2026 for SUNRISE-PD Phase 2b in Parkinson’s disease; ADDRESS-LC Phase 2 in Long COVID.
• Bezisterim showed a smaller mean worsening than placebo on MDS-UPDRS Part I-III and total in an ITT set of 57 patients.
• BIV201, a continuous IV terlipressin formulation for ascites, described as Phase 3-ready with an FDA-agreed design, Fast Track, Orphan status.
• Pipeline materials cited US annual sales potential of $3 billion for Parkinson’s, $10 billion for Long COVID, $30 billion for Alzheimer’s, $1.6 billion for ascites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.